Absci (NASDAQ:ABSI) 주식

Absci

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Cathie Wood's Buys The Dip In Tempus AI, Coinbase But Sells Ark's Bitcoin ETF Shares Amid Crypto Meltdown

Equities

News

Markets

Tech

ETFs

ABSI

ARKF

ARKK

ARKQ

ARKW

IBTA

PATH

PSNL

RBLX

ROKU

RXRX

금요일, 캐시 우드가 이끄는 아크 인베스트가 몇 가지 주요 거래를 진행했다. 이 거래는 로블록스(NYSE:RBLX), 로쿠(NASDAQ:ROKU), 유아이패스(NYSE:PATH), 아이보타(NYSE:IBTA), 퍼스널리스(NGM:PSNL), 앱시(NASDAQ:ABSI) 그리고 리커전 파마슈티컬스(NASDAQ:RXRX)와 같은 주식들에 대한 활동이 두드러졌다.

캐시 우드의 아크 인베스트가 시장 하락에 로블록스, 로쿠 및 유아이패스 매도

$BTC

ACCD

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

ARKG

COIN

DKNG

IRDM

KSPI

화요일(25일) 캐시 우드가 이끄는 아크 인베스트는 중요한 거래를 진행했다.

아크 인베스트: 템퍼스AI 및 코인베이스 저가매수, 아크 비트코인 ETF 주식 매도

ARKX

ESLT

ILMN

NTLA

OKLO

화요일(21일) 캐시 우드가 이끄는 아크 인베스트는 애콜레이드(NASDAQ:ACCD), 디어(NYSE:DE), 인텔리아 테라퓨틱스(NASDAQ:NTLA), 유아이패스(NYSE:PATH), 카메코(NYSE:CCJ), 오클로(NYSE:OKLO), 일루미나(NASDAQ:ILMN), 엘빗 시스템즈(NASDAQ:ESLT), 앱사이(NASDAQ:ABSI)와 관련된 상당한 거래를 진행했다. 

아크 인베스트, 트럼프의 정책에 따라 방산주·에너지주 투자

Absci Corp

BigBear.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>), a leading provider of AI-powered decision intelligence solutions for defense and national security, today announced that the U.S. Department of Defense (DoD) has awarded the company a 3.5-year, $13.2M sole source contract to support the Chairman of the Joint Chiefs of Staff's (CJCS) Directorate for Force Management (J-35). BigBear.ai will deliver and maintain the DoD Joint Staff J-35's ORION Decision Support Platform (DSP) which provides automated force management capabilities and data analytics to the DoD's Joint Planning and Execution Community (JPEC).

Contracts

BBAI

BigBear.ai Awarded 3.5-Year $13.2M Contract To Modernize Critical Department Of Defense Force Management Platform

<a href="https://www.globenewswire.com/Tracker?data=j0_DB2-hJBveatu6FOxheeN94qG_hZTjxlcaQygFOFXoin3SqEnEuBfMv-FtSYtQ0h5zUTGgNVB0jbEYztz0LGKyAliulvh5_nz8rlYXMuY=">BioCardia&#xAE;, Inc</a>.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office has granted Japanese Patent No. 7641330 titled "Radial and Transendocardial Delivery Catheter" with a patent term that will expire on or after September 30, 2034.

Biotech

Global

General

BCDA

BioCardia Announces That The Japan Patent Office Has Granted Japanese Patent No. 7641330 Titled "Radial And Transendocardial Delivery Catheter"

Fintech firm Rocket Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) <a href="https://www.benzinga.com/pressreleases/25/03/n44215457/rocket-companies-to-acquire-redfin-accelerating-purchase-mortgage-strategy" target="_blank" rel="noreferrer noopener">agreed to acquire</a> Redfin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>), a digital real estate platform, in an all-stock transaction valued at $12.50 per share, or approximately $1.75 billion in equity.
Under the terms of the agreement, Redfin shareholders will receive 0.7926 shares of Rocket Class A common stock for each Redfin share—a 63% premium over Redfin's 30-day volume-weighted average price. Rocket shareholders will own approximately 95% of the combined company upon completion, with Redfin shareholders holding the remaining 5%.
"Rocket and Redfin's approaches to lending and brokerage service have always been two halves of one vision to make the whole home-buying process magical," said Glenn Kelman, CEO of Redfin. "We want a customer to be able to check her phone to find out what she can afford, see which homes are just right for her, schedule a tour with a local, expert Redfin agent, and get pre-qualified for a loan—all in a matter of minutes."
See Also: <a href="https://www.benzinga.com/news/25/03/44213871/canadas-next-pm-mark-carney-vows-to-win-trade-war-with-trump-says-americans-should-make-no-mistake">Canada&#8217;s Next PM Mark Carney Vows To Win Trade War With Trump</a>
Redfin boasts 50 million monthly visitors, and one million active listings.
Detroit-based Rocket expects the deal to accelerate its purchase mortgage growth by integrating real estate search, brokerage, financing, title, and servicing—building on an 8% year-over-year increase in its 2024 purchase market share. 
With a combined 14 petabytes of data spanning 100 million properties, the company plans to enhance its AI capabilities to deliver more personalized, seamless, and automated consumer experiences.
Financially, the transaction is projected to generate over $200 million in annual run-rate synergies by 2027, including $140 million in cost reductions and $60 million in new revenue opportunities. The deal is expected to be accretive to Rocket's adjusted earnings per share by the end of 2026.
The deal is expected to close in mid-to-late 2025, pending shareholder and regulatory approval. Kelman will continue to lead Redfin, reporting to Rocket CEO Varun Krishna.
Additionally, Rocket announced that it would eliminate its complex "Up-C" and high-vote/low-vote structure, reducing four classes of stock to two and enhancing transparency and flexibility for future acquisitions. Gilbert and other Rock Holdings shareholders will hold standard one-vote-per-share common stock directly in Rocket, replacing their current 10-vote shares.
Special Dividend: Rocket declared a one-time cash dividend of $0.80 per Class A share, payable April 3, 2025, to shareholders of record as of March 20.
Price Action: Rocket shares are trading lower by 10.84% at $14.06 and RDFN higher by 76.12% at $10.25 premarket on Monday&#8217;s last check.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/25/03/44202239/deal-dispatch-tiktok-walgreens-raizen">Deal Dispatch: Clock Ticks On TikTok, Raizen Explores Asset Sale, Investors Urge Walgreens To Go Private</a></li>
</ul>
Image: Shutterstock

RDFN

Rocket Wants $1.75 Billion Redfin Deal To Change How America Buys Homes

Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5 million. The Bayview site includes manufacturing, laboratory, warehousing and office space, and is fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
As part of the agreement, Emergent will retain the rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene. Emergent continues to operate a streamlined manufacturing network, including facilities in Lansing, Michigan and Winnipeg, Manitoba, Canada capable of serving strategic partners and supporting large-scale projects.

Asset Sales

Emergent BioSolutions Announces Sale Of Baltimore-Bayview Manufacturing Site To Syngene International For $36.5M

WIIM

ServiceNow shares are trading lower. The company announced it signed a definitive agreement to acquire Moveworks for $2.85 billion.

Kevin O'Leary, also known as Mr. Wonderful, is speaking directly as always. In a recent post on X, the investor and &#8220;Shark Tank&#8221; star said, &#8220;Prices aren't going down! Eggs, energy, housing—all still sky-high.&#8221; And now, with <a href="https://www.benzinga.com/personal-finance/25/03/44068922/the-tariffs-are-going-forward-on-time-on-schedule-trump-confirms-canada-and-mexico-tariffs-what-should-u-s-consumers-expect">tariffs on Mexico and Canada</a>, things could get even more expensive.
<h2 class="wp-block-heading">Housing Costs Could Get Worse</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Prices aren't going down! eggs, energy, housing—all still sky-high. Now, add potential tariffs on Mexico and Canada. That means lumber prices up, housing even more expensive. Canada's in limbo without a prime minister, and the U.S. is playing hardball. This is all part of the… <a href="https://t.co/sVqRod6ORw">pic.twitter.com/sVqRod6ORw</a>
&mdash; Kevin O&#39;Leary aka Mr. Wonderful (@kevinolearytv) <a href="https://twitter.com/kevinolearytv/status/1896732730374693193?ref_src=twsrc%5Etfw">March 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share today.</a></li>
</ul>
O'Leary warns that tariffs could make an already tough housing market even worse. &#8220;Lumber prices up, housing even more expensive,&#8221; he <a href="https://x.com/kevinolearytv/status/1896732730374693193">posted</a>. He explains that if tariffs are placed on Canada and Mexico, it would drive up the cost of lumber, which is a key material for home construction.
According to O'Leary, the <a href="https://www.benzinga.com/money/timber-reits">lumber industry</a> isn't in a position to quickly adjust. &#8220;The lumber industry just yesterday and today said, ‘Look, we can&#8217;t make up this capacity for at least four to five years,'&#8221; he said. That means even if demand remains steady, prices could stay high for years to come.
Trending: <a href="https://www.benzinga.com/money/startengine-own">The $1.3 Billion Startup Investment Boom: How This Company's Explosive Growth Is Opening Doors For Everyday Investors With A New $500 Minimum</a>
<h2 class="wp-block-heading">Canada's Uncertain Position</h2>
O'Leary also points out that Canada is at a disadvantage in these negotiations. With the federal leadership in limbo, provincial leaders from Ontario, Alberta, and Saskatchewan are scrambling to handle trade talks in Washington. These provinces are especially affected because they are key players in trade, particularly in the energy sector.
<h2 class="wp-block-heading">A Strategy to Bring Investment Back</h2>
Despite the immediate concerns, O'Leary believes this is part of a long-term strategy to bring more investment back to the U.S. &#8220;These are volatile times,&#8221; he admitted. However, he sees the negotiations as part of a push to &#8220;get back more investment into the U.S. and a balance on trade imbalances, country by country by country.&#8221;
See Also: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">Trade War Heating Up</h2>
Canadian Prime Minister Justin Trudeau recently announced that Canada would <a href="https://www.benzinga.com/25/03/44102599/canadian-pm-justin-trudeau-retaliates-with-25-tariffs-on-us-goods-amid-escalating-trade-war">impose retaliatory tariffs</a> on U.S. imports in response to President Donald Trump's 25% levies on Canadian goods. The measures include a 25% tariff on CA$30 billion worth of U.S. goods, effective immediately, with an additional CA$125 billion in U.S. products facing the same tariff in three weeks.
Trump fired back with a post on Truth Social, warning that any retaliatory tariffs from Canada would be met with equal measures. &#8220;Please explain to Governor Trudeau, of Canada, that when he puts on a Retaliatory Tariff on the U.S., our Reciprocal Tariff will immediately increase by a like amount!&#8221; Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/114105388432604284">wrote</a>.
While no one knows exactly how this will play out, uncertainty is here to stay, at least for now. &#8220;[If tariffs] go on, there won't be any immediate change to anything. It&#8217;ll be a continued negotiation,&#8221; O'Leary noted. For consumers, that means no quick drop in prices anytime soon.
Read Next:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
</ul>

Kevin O'Leary Says, 'Prices Aren't Going Down!' Eggs, Energy, And Housing Remain 'Sky-High,' But He Thinks It's Part Of A Bigger Strategy

&nbsp;NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that acceptance has been received by Capricor Therapeutics, Inc. (Headquarters: California, USA, CEO: Linda Marbán, (Headquarters: California, USA, CEO: Linda Marbán, NASDAQ:<a href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>)&nbsp;from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) filing for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy ("DMD") cardiomyopathy.&nbsp;The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date of August 31, 2025, and at this time, the FDA has not identified any potential review issues.
Nippon Shinyaku and Capricor entered into an exclusive distribution agreement for deramiocel for the U.S. in January 2022. NS Pharma will be exclusively responsible for commercialization and distribution of deramiocel in the U.S.

CAPR

Capricor Accepted By FDA For Deramiocel BLA Filing For DMD Cardiomyopathy, Priority Review Granted, PDUFA Date Set For August 31, 2025; NS Pharma To Commercialize In U.S.

Tariffs, <a href="https://www.benzinga.com/topic/federal-reserve">federal spending cuts</a> and CoWoS (Chip-on-Wafer-on-Substrate) slowdowns are shaking up the hardware and networking sector. JPMorgan analyst Samik Chatterjee weighs in on which stocks are best equipped to weather the storm.
<h2 class="wp-block-heading">Tariffs: Who's Feeling The Heat?</h2>
Companies loaded with software-driven hardware are dodging the worst of the tariff blow, while commoditized IT hardware players are absorbing rising costs. Networking leaders like Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) and Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) have an edge, given their ability to pass costs down the chain.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/44005208/nvidia-ai-juggernaut-rolls-on-but-can-arista-cisco-keep-up">Nvidia Dominance Continues As AI Demand Grows: Can Arista, Cisco Keep Up?</a>
Meanwhile, PC and server makers face tighter margins, with limited room to hike prices without losing customers.
Cisco's CFO has already factored in the tariff impact, while Arista's team says they've been planning for China risks ahead of time. The wildcard? 
Storage and networking equipment appear largely insulated, but competitive server pricing could make cost pass-throughs a challenge.
<h2 class="wp-block-heading">Federal Spending Cuts: Who's At Risk?</h2>
A slowdown in government IT budgets might hit device makers harder than infrastructure players. Cisco, with more than 5% of revenue tied to federal spending, could see near-term pressure, but JPMorgan suggests long-term benefits from federal tech modernization. 
Channel partners like CDW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) also have notable exposure but are downplaying risks for now.
<h2 class="wp-block-heading">CoWoS Cuts: Nvidia's Supply Chain Feels The Squeeze</h2>
Recent CoWoS order cuts by Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are reshuffling supplier valuations. The biggest impact? 
Nvidia-linked players like Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>), Amphenol Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) and Coherent Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) could face multiple compression, even if revenue estimates remain intact.
Cisco and Arista look relatively shielded from tariff pain, Nvidia's supply chain faces valuation headwinds and federal spending concerns might be a short-term roadblock for key players.
With hardware margins under pressure, JPMorgan's take is clear: software-rich and infrastructure-driven companies have the best shot at staying ahead.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44214424/move-over-deepseek-not-so-fast-chinas-manus-ai-goes-viral-but-early-users-say-it-crashes-loops-and-fumbles-the-basics">Move Over DeepSeek? Not So Fast: China&#8217;s Manus AI Goes Viral, But Early Users Say It Crashes, Loops, And Fumbles The Basics</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Analyst Ratings

Trading Ideas

AMZN

ANET

COHR

CSCO

NVDA

Cisco, Nvidia, Arista Tackle Tariff Turmoil: Who's Best Positioned?

BNTX

BioNTech SE shares are trading lower. The company reported Q4 financial results.

Raymond James analyst John Freeman downgrades Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) from Strong Buy to Outperform and lowers the price target from $81 to $64.

Downgrades

Price Target

Raymond James Downgrades Occidental Petroleum to Outperform, Lowers Price Target to $64

Emerson Electric shares are trading lower after Barclays downgraded the stock from Equal-Weight to Underweight and cut its price target from $135 to $110.

ServiceNow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) is nearing a deal to snap <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">artificial intelligence firm</a>&nbsp;Moveworks.
The purchase could value Moveworks at close to $3 billion, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-03-10/servicenow-nears-deal-to-buy-ai-assistant-maker-moveworks?sref=TBDibEcD" rel="noreferrer noopener">reports</a>. Moveworks provides companies like Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with AI assistants to handle employee requests.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43788975/amd-closing-competitive-gpu-gap-with-nvidia-gains-market-share-from-intel-in-client-and-server-markets-analyst" rel="noreferrer noopener">AMD Closing Competitive GPU Gap With Nvidia, Gains Market Share From Intel In Client And Server Markets: Analyst</a>
The company, backed by Kleiner Perkins and&nbsp;Lightspeed Venture Partners, was worth $2.1 billion in a&nbsp;2021 funding round.
ServiceNow makes applications that help firms organize and automate their personnel and information technology operations.
Last week, ServiceNow and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) launched AI agents for <a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44074819/servicenow-unveils-ai-agents-for-telecoms-in-collaboration-with-nvidia" rel="noreferrer noopener">telecom service improvements</a>.
ServiceNow reported fourth-quarter revenue of $2.96 billion, up 21%, which aligns with <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43320721/servicenow-q4-earnings-revenue-miss-eps-in-line-still-in-early-days-of-massive-ai-opportunity" rel="noreferrer noopener">the&nbsp;consensus estimate</a>. The company reported fourth-quarter adjusted earnings of $3.67 per share, which aligns with analyst estimates.
ServiceNow expects first-quarter subscription revenue of $2.995 billion-$3 billion. ServiceNow held $5.76 billion in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43318968/servicenow-reports-fourth-quarter-and-full-year-2024-financial-results-board-of-directors-authoriz" rel="noreferrer noopener">cash and equivalents</a> as of December 31, 2024.
Price Action: NOW stock is down 3.26% at $822.87 premarket at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44200350/salesforce-ai-expansion-sparks-analyst-optimism-400-price-forecast-set" target="_blank" rel="noreferrer noopener">Salesforce Is Trading Below 200-DMA, But Goldman Sachs Sees Huge Stock Upside After Agentforce 2dx Unveil</a></li>
</ul>
Image Via Shutterstock

Media

AVGO

ServiceNow Eyes $3 Billion AI Deal, Targets Boost From Moveworks Chatbot Tech

Sunshine Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has acquired the rights to two gastrointestinal drugs and already launched one. The second is planned to be launched in the next 9 months.
The newly launched drug is Prucalopride, a generic version of Resotran&#xAE;. In the United States, Prucalopride is sold under the brand name, Motegrity&#xAE;. Prucalopride is indicated for the treatment of chronic idiopathic constipation in adult women for whom laxatives do not provide adequate relief. Prucalopride works by selectively stimulating the 5-HT4 receptors in the gastrointestinal tract. This action promotes cholinergic and non-adrenergic neurotransmission by enteric neurons, leading to increased peristaltic reflex, intestinal secretions, and overall gastrointestinal motility.
Nora Pharma's Prucalopride is available in blisters packs of 28 tablets for the Canadian market in strengths of 1 mg and 2 mg.

SBFM

Sunshine Biopharma's Nora Pharma Acquires Rights To Two Gastrointestinal Drugs; Already Launched Prucalopride For Chronic Constipation, Second Drug Launch Planned In The Next 9 Months; No Financial Terms Disclosed

Raymond James analyst John Freeman downgrades APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) from Strong Buy to Outperform and lowers the price target from $45 to $32.

Raymond James Downgrades APA to Outperform, Lowers Price Target to $32

No gainer in today's Pre-market session. 
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">214.53</td>
<td align="right">-4.01</td>
<td align="right">-1.84</td>
<td>69.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">132.08</td>
<td align="right">-2.17</td>
<td align="right">-1.62</td>
<td>3.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">202.37</td>
<td align="right">-3.30</td>
<td align="right">-1.61</td>
<td>4.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">98.73</td>
<td align="right">-1.56</td>
<td align="right">-1.56</td>
<td>1.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.40</td>
<td align="right">-0.72</td>
<td align="right">-1.47</td>
<td>544.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">86.81</td>
<td align="right">-1.01</td>
<td align="right">-1.16</td>
<td>1.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">148.21</td>
<td align="right">-1.07</td>
<td align="right">-0.72</td>
<td>10.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">76.92</td>
<td align="right">-0.37</td>
<td align="right">-0.48</td>
<td>9.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.32</td>
<td align="right">-0.15</td>
<td align="right">-0.36</td>
<td>3.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.70</td>
<td align="right">-0.16</td>
<td align="right">-0.20</td>
<td>32.8K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For March 10, 2025

Raymond James analyst Ryan Deschner upgrades Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) from Outperform to Strong Buy and raises the price target from $9 to $29.

Upgrades

TRVI

Raymond James Upgrades Trevi Therapeutics to Strong Buy, Raises Price Target to $29

Barclays analyst Ramsey El-Assal maintains EPAM Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) with a Overweight and lowers the price target from $290 to $270.

EPAM

Barclays Maintains Overweight on EPAM Systems, Lowers Price Target to $270

On Monday, Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in <a href="http://Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains" target="_blank" rel="noreferrer noopener">vivo base editing</a>.
The initial safety and efficacy data reported are from all nine patients as of February 26, the data <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44214548/beam-therapeutics-announces-positive-initial-data-for-beam-302-in-the-phase-12-trial-in-alpha-1-an" rel="noreferrer noopener">cut-off date</a>.
Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was well tolerated, with single doses of BEAM-302 leading to durable dose-dependent correction of the disease-causing mutation.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42393770/beam-therapeutics-unveils-new-safety-efficacy-data-from-sickle-cell-disease-candidate-stock-gains" rel="noreferrer noopener">Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains</a>
Alpha-1 antitrypsin (AAT) deficiency is&nbsp;a genetic disorder that can cause lung disease and liver disease.&nbsp;It occurs when the body doesn&#8217;t produce enough AAT, a protein that protects the lungs and liver.&nbsp;
Following a single infusion of BEAM-302, rapid, durable and dose-dependent increases in total AAT, a new production of corrected M-AAT and decreases in mutant Z-AAT were observed in circulation.
<ul>
<li>Changes in total AAT were observed as early as Day 7, plateaued around Day 21 and were maintained for the duration of follow-up (up to Month 6 in the 15 mg cohort, Month two in the 30 mg cohort and Day 28 in the 60 mg cohort).</li>
<li>Increased total AAT was functional.</li>
</ul>
Beam plans to continue the dose-escalation portion of Part A of the ongoing Phase 1/2 trial, including enrolling and dosing a fourth dose cohort. It also expects to report further data at a medical conference in the second half of 2025.
In addition, the company plans to dose the first patient in Part B, including AATD patients with mild to moderate liver disease, in the second half of 2025.
Concurrently, Beam Therapeutics priced the underwritten offering of 16.15 million shares at $28.48 per share and pre-funded warrants to purchase 1.4 million at $28.47 per pre-funded warrant, with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44214581/beam-therapeutics-announces-pricing-of-underwritten-offering" rel="noreferrer noopener">approximately $500 million gross proceeds</a>.
Price Action: BEAM stock is down 3.44% at $27.50 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44217345/whats-going-on-with-palantir-stock-premarket-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Palantir Stock Premarket On Monday?</a></li>
</ul>
Photo: Shutterstock

Health Care

Financing

Offerings

BEAM

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Barclays analyst Karen Short maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Equal-Weight and raises the price target from $940 to $980.

COST

Barclays Maintains Equal-Weight on Costco Wholesale, Raises Price Target to $980

ServiceNow's agentic AI and automation strengths plus Moveworks' front-end AI assistant and enterprise search technology to accelerate enterprise AI adoption and innovation
Together with Moveworks, ServiceNow will drive use of its agentic AI platform across key growth areas including CRM
ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), the AI platform for business transformation, today announced it has signed a definitive agreement to acquire Moveworks. The acquisition will combine ServiceNow's agentic AI and automation strengths with Moveworks' front-end AI assistant and enterprise search technology to unlock new experiences for every employee for every corner of the business. Following closing, together with Moveworks, ServiceNow – with thousands of AI agents already deployed – will continue to drive use of its agentic AI ServiceNow Platform to accelerate enterprise adoption and innovation across key growth areas including CRM.
&nbsp;
Transaction details
Under the terms of the agreement, ServiceNow will acquire Moveworks for $2.85 billion, subject to customary purchase price adjustments, payable in a combination of cash and stock. The transaction is expected to close in the second half of 2025, subject to customary regulatory approvals and closing conditions.

ServiceNow Has Signed A Definitive Agreement To Acquire Moveworks For $2.85B

Press Releases

Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health

Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery

Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

Small Cap

Opinion

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference

FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape

Absci to Participate in the TD Cowen 45th Annual Health Care Conference

Absci to Participate in the KeyBanc Capital Markets Healthcare Forum

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025

Comments

Absci

뉴스

파트너 / 기고자

벤징가 글로벌